Cargando…

Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study

Background: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Becciolini, Andrea, Parisi, Simone, Del Medico, Patrizia, Farina, Antonella, Visalli, Elisa, Molica Colella, Aldo Biagio, Lumetti, Federica, Caccavale, Rosalba, Scolieri, Palma, Andracco, Romina, Girelli, Francesco, Bravi, Elena, Colina, Matteo, Volpe, Alessandro, Ianniello, Aurora, Ditto, Maria Chiara, Nucera, Valeria, Franchina, Veronica, Platè, Ilaria, Donato, Eleonora Di, Amato, Giorgio, Salvarani, Carlo, Bernardi, Simone, Lucchini, Gianluca, De Lucia, Francesco, Molica Colella, Francesco, Santilli, Daniele, Mansueto, Natalia, Ferrero, Giulio, Marchetta, Antonio, Arrigoni, Eugenio, Foti, Rosario, Sandri, Gilda, Bruzzese, Vincenzo, Paroli, Marino, Fusaro, Enrico, Ariani, Alarico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953385/
https://www.ncbi.nlm.nih.gov/pubmed/36830969
http://dx.doi.org/10.3390/biomedicines11020433
_version_ 1784893865299279872
author Becciolini, Andrea
Parisi, Simone
Del Medico, Patrizia
Farina, Antonella
Visalli, Elisa
Molica Colella, Aldo Biagio
Lumetti, Federica
Caccavale, Rosalba
Scolieri, Palma
Andracco, Romina
Girelli, Francesco
Bravi, Elena
Colina, Matteo
Volpe, Alessandro
Ianniello, Aurora
Ditto, Maria Chiara
Nucera, Valeria
Franchina, Veronica
Platè, Ilaria
Donato, Eleonora Di
Amato, Giorgio
Salvarani, Carlo
Bernardi, Simone
Lucchini, Gianluca
De Lucia, Francesco
Molica Colella, Francesco
Santilli, Daniele
Mansueto, Natalia
Ferrero, Giulio
Marchetta, Antonio
Arrigoni, Eugenio
Foti, Rosario
Sandri, Gilda
Bruzzese, Vincenzo
Paroli, Marino
Fusaro, Enrico
Ariani, Alarico
author_facet Becciolini, Andrea
Parisi, Simone
Del Medico, Patrizia
Farina, Antonella
Visalli, Elisa
Molica Colella, Aldo Biagio
Lumetti, Federica
Caccavale, Rosalba
Scolieri, Palma
Andracco, Romina
Girelli, Francesco
Bravi, Elena
Colina, Matteo
Volpe, Alessandro
Ianniello, Aurora
Ditto, Maria Chiara
Nucera, Valeria
Franchina, Veronica
Platè, Ilaria
Donato, Eleonora Di
Amato, Giorgio
Salvarani, Carlo
Bernardi, Simone
Lucchini, Gianluca
De Lucia, Francesco
Molica Colella, Francesco
Santilli, Daniele
Mansueto, Natalia
Ferrero, Giulio
Marchetta, Antonio
Arrigoni, Eugenio
Foti, Rosario
Sandri, Gilda
Bruzzese, Vincenzo
Paroli, Marino
Fusaro, Enrico
Ariani, Alarico
author_sort Becciolini, Andrea
collection PubMed
description Background: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to analyze the predictors of clinical response. Methods: All PsA consecutive patients treated with apremilast in fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline, 6 months, and 12 months were recorded. The Mann–Whitney test and chi-squared tests assessed the differences between independent groups, whereas the Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. Logistic regressions verified if there were factors associated with achievement of DAPSA low disease activity or remission at 6 and 12 months. Results: DAPSA low disease activity or remission rates at 6 and 12 months were observed, respectively, in 42.7% (n = 125) and 54.9% (n = 161) patients. Baseline DAPSA was inversely associated with the odds of achieving low disease activity or remission at 6 months (odds ratio (OR) 0.841, 95% confidence interval (CI) 0.804–0.879; p < 0.01) and at 12 months (OR 0.911, 95% CI 0.883–0.939; p < 0.01). Conclusions: Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA.
format Online
Article
Text
id pubmed-9953385
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99533852023-02-25 Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study Becciolini, Andrea Parisi, Simone Del Medico, Patrizia Farina, Antonella Visalli, Elisa Molica Colella, Aldo Biagio Lumetti, Federica Caccavale, Rosalba Scolieri, Palma Andracco, Romina Girelli, Francesco Bravi, Elena Colina, Matteo Volpe, Alessandro Ianniello, Aurora Ditto, Maria Chiara Nucera, Valeria Franchina, Veronica Platè, Ilaria Donato, Eleonora Di Amato, Giorgio Salvarani, Carlo Bernardi, Simone Lucchini, Gianluca De Lucia, Francesco Molica Colella, Francesco Santilli, Daniele Mansueto, Natalia Ferrero, Giulio Marchetta, Antonio Arrigoni, Eugenio Foti, Rosario Sandri, Gilda Bruzzese, Vincenzo Paroli, Marino Fusaro, Enrico Ariani, Alarico Biomedicines Article Background: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to analyze the predictors of clinical response. Methods: All PsA consecutive patients treated with apremilast in fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline, 6 months, and 12 months were recorded. The Mann–Whitney test and chi-squared tests assessed the differences between independent groups, whereas the Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. Logistic regressions verified if there were factors associated with achievement of DAPSA low disease activity or remission at 6 and 12 months. Results: DAPSA low disease activity or remission rates at 6 and 12 months were observed, respectively, in 42.7% (n = 125) and 54.9% (n = 161) patients. Baseline DAPSA was inversely associated with the odds of achieving low disease activity or remission at 6 months (odds ratio (OR) 0.841, 95% confidence interval (CI) 0.804–0.879; p < 0.01) and at 12 months (OR 0.911, 95% CI 0.883–0.939; p < 0.01). Conclusions: Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA. MDPI 2023-02-02 /pmc/articles/PMC9953385/ /pubmed/36830969 http://dx.doi.org/10.3390/biomedicines11020433 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Becciolini, Andrea
Parisi, Simone
Del Medico, Patrizia
Farina, Antonella
Visalli, Elisa
Molica Colella, Aldo Biagio
Lumetti, Federica
Caccavale, Rosalba
Scolieri, Palma
Andracco, Romina
Girelli, Francesco
Bravi, Elena
Colina, Matteo
Volpe, Alessandro
Ianniello, Aurora
Ditto, Maria Chiara
Nucera, Valeria
Franchina, Veronica
Platè, Ilaria
Donato, Eleonora Di
Amato, Giorgio
Salvarani, Carlo
Bernardi, Simone
Lucchini, Gianluca
De Lucia, Francesco
Molica Colella, Francesco
Santilli, Daniele
Mansueto, Natalia
Ferrero, Giulio
Marchetta, Antonio
Arrigoni, Eugenio
Foti, Rosario
Sandri, Gilda
Bruzzese, Vincenzo
Paroli, Marino
Fusaro, Enrico
Ariani, Alarico
Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
title Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
title_full Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
title_fullStr Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
title_full_unstemmed Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
title_short Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
title_sort predictors of dapsa response in psoriatic arthritis patients treated with apremilast in a retrospective observational multi-centric study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953385/
https://www.ncbi.nlm.nih.gov/pubmed/36830969
http://dx.doi.org/10.3390/biomedicines11020433
work_keys_str_mv AT beccioliniandrea predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT parisisimone predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT delmedicopatrizia predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT farinaantonella predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT visallielisa predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT molicacolellaaldobiagio predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT lumettifederica predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT caccavalerosalba predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT scolieripalma predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT andraccoromina predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT girellifrancesco predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT bravielena predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT colinamatteo predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT volpealessandro predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT iannielloaurora predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT dittomariachiara predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT nuceravaleria predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT franchinaveronica predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT plateilaria predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT donatoeleonoradi predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT amatogiorgio predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT salvaranicarlo predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT bernardisimone predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT lucchinigianluca predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT deluciafrancesco predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT molicacolellafrancesco predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT santillidaniele predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT mansuetonatalia predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT ferrerogiulio predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT marchettaantonio predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT arrigonieugenio predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT fotirosario predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT sandrigilda predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT bruzzesevincenzo predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT parolimarino predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT fusaroenrico predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy
AT arianialarico predictorsofdapsaresponseinpsoriaticarthritispatientstreatedwithapremilastinaretrospectiveobservationalmulticentricstudy